Phase two, with a $520,000 federal investment, provides funding for further development of diagnostic tests, including the pneumonia test, that will eventually be sold commercially.
Le second volet, qui comprend un investissement de 520 000 dollars, financera le développement d’autres tests de diagnostic, dont le test de la pneumonie, qui finira par être commercialisé.